Galera Therapeutics (GRTX)
(Delayed Data from NSDQ)
$0.19 USD
0.00 (2.03%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $0.18 -0.01 (-3.38%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Galera Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 49 | 51 | 73 | 71 | 51 |
Income After Depreciation & Amortization | -49 | -51 | -73 | -71 | -51 |
Non-Operating Income | 2 | 1 | 0 | 1 | 2 |
Interest Expense | 11 | 12 | 7 | 5 | 3 |
Pretax Income | -59 | -62 | -81 | -74 | -52 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -59 | -62 | -81 | -74 | -52 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -59 | -62 | -81 | -74 | -52 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -49 | -51 | -73 | -70 | -50 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -49 | -51 | -73 | -71 | -51 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 44.55 | 27.09 | 25.79 | 24.87 | 3.63 |
Diluted EPS Before Non-Recurring Items | -1.33 | -2.30 | -3.12 | -2.98 | -16.31 |
Diluted Net EPS (GAAP) | -1.33 | -2.30 | -3.12 | -2.98 | -16.31 |
Fiscal Year end for Galera Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 5.18 | 13.39 | 16.81 | 13.88 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -5.18 | -13.39 | -16.81 | -13.88 |
Non-Operating Income | NA | 0.29 | 0.41 | 0.49 | 0.39 |
Interest Expense | NA | 0.70 | 2.09 | 4.40 | 4.22 |
Pretax Income | NA | -5.59 | -15.07 | -20.71 | -17.71 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -5.59 | -15.07 | -20.71 | -17.71 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -5.59 | -15.07 | -20.71 | -17.71 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 54.39 | 45.48 | 42.92 | 35.20 |
Diluted EPS Before Non-Recurring Items | NA | -0.10 | -0.33 | -0.48 | -0.50 |
Diluted Net EPS (GAAP) | NA | -0.02 | -0.33 | -0.48 | -0.50 |